These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 19149612)

  • 1. Targeted therapies in lung cancer.
    Pirker R; Filipits M
    Curr Pharm Des; 2009; 15(2):188-206. PubMed ID: 19149612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better….
    Di Maio M; Morabito A; Piccirillo MC; Daniele G; Giordano P; Costanzo R; Sandomenico C; Montanino A; Rocco G; Perrone F
    Curr Pharm Des; 2014; 20(24):3901-13. PubMed ID: 24191956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
    Pirker R; Minar W; Filipits M
    Clin Lung Cancer; 2008; 9 Suppl 3():S109-15. PubMed ID: 19419924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of monoclonal antibodies in non small cell lung cancer.
    Filipits M
    J BUON; 2009 Sep; 14 Suppl 1():S147-52. PubMed ID: 19785057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
    Jotte RM; Spigel DR
    Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung.
    Goss GD; Spaans JN
    Oncologist; 2016 Feb; 21(2):205-13. PubMed ID: 26768483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
    Harichand-Herdt S; Ramalingam SS
    Semin Thorac Cardiovasc Surg; 2008; 20(3):217-23. PubMed ID: 19038731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung Cancer.
    Takeda M; Nakagawa K
    Curr Cancer Drug Targets; 2015; 15(9):792-802. PubMed ID: 26567882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer.
    Bonomi PD; Gandara D; Hirsch FR; Kerr KM; Obasaju C; Paz-Ares L; Bellomo C; Bradley JD; Bunn PA; Culligan M; Jett JR; Kim ES; Langer CJ; Natale RB; Novello S; Pérol M; Ramalingam SS; Reck M; Reynolds CH; Smit EF; Socinski MA; Spigel DR; Vansteenkiste JF; Wakelee H; Thatcher N
    Ann Oncol; 2018 Aug; 29(8):1701-1709. PubMed ID: 29905778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irreversible EGFR inhibitors in the treatment of advanced NSCLC.
    Maione P; Rossi A; Bareschino M; Sacco PC; Schettino C; Casaluce F; Sgambato A; Gridelli C
    Curr Pharm Des; 2014; 20(24):3894-900. PubMed ID: 24138713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.
    Chen YM
    J Chin Med Assoc; 2013 May; 76(5):249-57. PubMed ID: 23683257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis.
    Chen P; Wang L; Liu B; Zhang HZ; Liu HC; Zou Z
    Eur J Clin Pharmacol; 2011 Mar; 67(3):235-43. PubMed ID: 21207017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies against EGFR in non-small cell lung cancer.
    Pirker R; Filipits M
    Crit Rev Oncol Hematol; 2011 Oct; 80(1):1-9. PubMed ID: 21109448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapies for advanced non-small cell lung cancer.
    Starakis I; Nikolakopoulos A; Mazokopakis EE
    Comb Chem High Throughput Screen; 2012 Sep; 15(8):641-55. PubMed ID: 22409867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR-directed monoclonal antibodies in non-small cell lung cancer.
    Pirker R
    Target Oncol; 2013 Mar; 8(1):47-53. PubMed ID: 23300028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extending outcomes: epidermal growth factor receptor-targeted monoclonal antibodies in non-small-cell lung cancer.
    Joy AA; Butts CA
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S24-9. PubMed ID: 19362943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer.
    Herbst RS; Sandler AB
    Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S7-S19. PubMed ID: 15638959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
    Marquez-Medina D; Popat S
    Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.
    Pakkala S; Ramalingam SS
    Clin Lung Cancer; 2009 Mar; 10 Suppl 1():S17-23. PubMed ID: 19362942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
    Sheng Z; Zhang Y
    Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.